reference/3274347

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/3274347

Outgoing Links

Predicate	Object
contentType	Comparative Study\|Journal Article
endingPage	78
issn	0920-1211
pageRange	71-78
publicationName	Epilepsy Research
startingPage	71
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_0290a64b5a82963d713a0b193b11bd83 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_3756248723e8a8819fceb90fd16e8d32
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_1f7fda0f1c0a9ce56f4b62b72a6484d6
bibliographicCitation	Rahman MM, Alatawi Y, Cheng N, Qian J, Plotkina AV, Peissig PL, Berg RL, Page D, Hansen RA. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Epilepsy Research. 2017 Sep;135():71–8. doi: 10.1016/j.eplepsyres.2017.06.007.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e6acad120e636f28515dc5aa66f9f579 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-8167-6931 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1a1e5ba119b858aad41afb4f15700503 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_52bfd19c0e2e00e8588ffd31fbdf3a1d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f9897fe3ba277c237262c43868d7c881 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_850e3be6c3e87d4c4f80d3995eaf1f8b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8cc5acf725dd98f5d9bb43cf9864b539 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a8a1020475d734cd9da7b88281e236e7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ce0bcb38278baac9936c3f46dce0334e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_314908615e65e880d00a3a3d1c0a97dc
date	201709
identifier	https://pubmed.ncbi.nlm.nih.gov/28641219 https://pubmed.ncbi.nlm.nih.gov/PMC5842137 https://doi.org/10.1016/j.eplepsyres.2017.06.007
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3587 https://portal.issn.org/resource/ISSN/0920-1211
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
discusses	http://id.nlm.nih.gov/mesh/M0003328 http://id.nlm.nih.gov/mesh/M0021908 http://id.nlm.nih.gov/mesh/M0137818 http://id.nlm.nih.gov/mesh/M0025275 http://id.nlm.nih.gov/mesh/M0109945 http://id.nlm.nih.gov/mesh/M0001382
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D016568Q000009 http://id.nlm.nih.gov/mesh/D014227Q000009 http://id.nlm.nih.gov/mesh/D002220Q000009 http://id.nlm.nih.gov/mesh/D000927Q000009 http://id.nlm.nih.gov/mesh/D016907 http://id.nlm.nih.gov/mesh/D002220Q000031
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D007722 http://id.nlm.nih.gov/mesh/D014227Q000627 http://id.nlm.nih.gov/mesh/D013405 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000078330 http://id.nlm.nih.gov/mesh/D016568Q000627 http://id.nlm.nih.gov/mesh/D004827Q000453 http://id.nlm.nih.gov/mesh/D002220Q000627 http://id.nlm.nih.gov/mesh/D004827Q000523 http://id.nlm.nih.gov/mesh/D014486 http://id.nlm.nih.gov/mesh/D012189 http://id.nlm.nih.gov/mesh/D004827Q000188 http://id.nlm.nih.gov/mesh/D014481 http://id.nlm.nih.gov/mesh/D011287 http://id.nlm.nih.gov/mesh/D000077213 http://id.nlm.nih.gov/mesh/D000927Q000627
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID34312 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7617 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2554 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3878

Total number of triples: 63.